Novoheart Collaborates with AstraZeneca to Develop World’s First Heart-in-a-Jar Model of Heart Failure

Novoheart Collaborates with AstraZeneca to Develop World’s First Heart-in-a-Jar Model of Heart Failure

Shots:

  • The collaboration initially focuses on developing in vitro, functional model of heart failure with HFpEF utilizing Novoheart’s 3-D human ventricular cardiac organoid chamber (hvCOC) technology which reproduces key phenotypic characteristics of HFpEF
  • The focus of the collaboration is to combine Novoheart’s hvCOC model with AstraZeneca’s expertise in heart failure to build the gap between in vivo animal models and clinical studies, thus accelerating the discovery process by providing human-specific preclinical data
  • Human heart-in-a-jar is the only human-engineered heart tissue available in the market which fabricated with specific cellular & matrix compositions and iPSCs, allowing control over patient’s physical and mechanical properties to mimic observation in HFpEF heart

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Novoheart